Globenewswire·2026-01-12 14:00Core Viewpoint - Avalon GloboCare Corp. has regained compliance with Nasdaq's minimum stockholders' equity requirement, allowing its common stock to continue being listed and traded on the Nasdaq Capital Market [1][2]. Financial Compliance - Nasdaq confirmed that Avalon is now in compliance with all applicable continued listing standards, leading to the cancellation of a previously scheduled hearing before the Nasdaq Hearings Panel [2]. - The company expressed satisfaction with its regained compliance, highlighting the progress made in strengthening its financial position and focusing on long-term shareholder value [3]. Growth Initiatives - With full Nasdaq compliance restored, Avalon is positioned to execute growth initiatives, including launching marketing for its generative AI video platform and expanding in precision diagnostics and strategic assets [3]. Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy and generative AI publishing and software through its subsidiary Avalon Quantum AI, LLC [4]. - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to develop additional diagnostic uses for this technology [4].